HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

周五，研究机构H.C. Wainwright维持了对专注于开发精神健康疾病治疗方案的临床阶段生物制药公司MindMed（NASDAQ:MNMD）的买入评级和55.00美元的目标价。目前该股交易价格为6.61美元，分析师们认为具有显著上涨空间，他们的目标价区间在16美元至55美元之间。该机构分析师强调，即将到来的三期临床试验结果将成为推动股价达到其目标价的潜在催化剂。根据InvestingPro数据 ...

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) had its price target decreased by investment analysts at Robert W.

Mind Medicine Inc. (MNMD)公布2024年第四季度财报,每股亏损0.41美元,高于市场预期的0.31美元亏损。受此影响,该公司股价盘前下跌4.12%。尽管当前面临挑战,但管理层对公司前景保持乐观,重点关注现金状况和临床试验进展。

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Mind Medicine Inc. ( ($MNMD) ) has released its Q4 earnings. Here is a breakdown of the information Mind Medicine Inc. presented to its investors.

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...

(NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth ...

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event. MindMed is a late-stage clinical ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health ...

Detailed price information for Mind Medicine Mindmed Inc (MNMD-Q) from The Globe and Mail including charting and trades.